IRRAS Announces First Global Patient Treatment with Newly Developed Hummingbird Solo ICP Monitoring System
· Initial patient treatment confirms system’s accuracy and ease of use · US launch of Hummingbird Solo system expands the Hummingbird ICP Monitoring product family, allowing IRRAS to more completely target global market valued at more than 300M EUR annuallyStockholm, August 5, 2020 – IRRAS AB, a commercial-stage medical technology company with a comprehensive portfolio of innovative products for neurocritical care, today announced the first patient treatment using the Hummingbird Solo, an additional line extension to its innovative Hummingbird ICP Monitoring product family that was